John W Baddley1, Sharon C-A Chen2,3, Carrie Huisingh4, Kaitlin Benedict5, Emilio E DeBess6, Eleni Galanis7,8, Brendan R Jackson5, Laura MacDougall8, Nicola Marsden-Haug9, Hanna Oltean9, John R Perfect10, Peter Phillips7,11, Tania C Sorrell2,3,12, Peter G Pappas4. 1. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. 2. Centre for Infectious Diseases and Microbiology, Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, The University of Sydney, Sydney, Australia. 3. Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, Australia. 4. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 5. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 6. Oregon State Department of Health, Portland, Oregon, USA. 7. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. 8. British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. 9. Washington State Department of Health, Olympia, Washington, USA. 10. Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA. 11. St Paul's Hospital, Department of Medicine, Vancouver, British Columbia, Canada. 12. Westmead Institute for Medical Research, Infectious Diseases Group, Sydney, Australia.
Abstract
BACKGROUND: Cryptococcosis due to Cryptococcus neoformans and Cryptococcus gattii varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment. METHODS: We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995-2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with C. gattii or C. neoformans infection. RESULTS: A total of 709 patients (452 C. neoformans; 257 C. gattii) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in C. gattii patients compared with C. neoformans (mean, 52.2 vs 36.0 days; P < .003), and there was a higher proportion of C. gattii patients without underlying disease (40.5% vs 10.2%; P < .0001). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with C. gattii than in those with C. neoformans (60.7% vs 32.1%; P < .0001). CNS or blood infections were more common in C. neoformans-infected patients (P ≤ .0001 for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with C. neoformans (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08-2.26]). CONCLUSIONS: This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.
BACKGROUND: Cryptococcosis due to Cryptococcus neoformans and Cryptococcus gattii varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment. METHODS: We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995-2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with C. gattii or C. neoformans infection. RESULTS: A total of 709 patients (452 C. neoformans; 257 C. gattii) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in C. gattii patients compared with C. neoformans (mean, 52.2 vs 36.0 days; P < .003), and there was a higher proportion of C. gattii patients without underlying disease (40.5% vs 10.2%; P < .0001). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with C. gattii than in those with C. neoformans (60.7% vs 32.1%; P < .0001). CNS or blood infections were more common in C. neoformans-infected patients (P ≤ .0001 for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with C. neoformans (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08-2.26]). CONCLUSIONS: This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.
Authors: Peter Phillips; Eleni Galanis; Laura MacDougall; Mei Y Chong; Robert Balshaw; Victoria J Cook; William Bowie; Theodore Steiner; Linda Hoang; Muhammad Morshed; Wayne Ghesquiere; David M Forrest; Diane Roscoe; Patrick Doyle; Pamela C Kibsey; Thomas Connolly; Yazdan Mirzanejad; Darby Thompson Journal: Clin Infect Dis Date: 2015-01-28 Impact factor: 9.079
Authors: Sharon C-A Chen; Monica A Slavin; Christopher H Heath; E Geoffrey Playford; Karen Byth; Deborah Marriott; Sarah E Kidd; Narin Bak; Bart Currie; Krispin Hajkowicz; Tony M Korman; William J H McBride; Wieland Meyer; Ronan Murray; Tania C Sorrell Journal: Clin Infect Dis Date: 2012-06-05 Impact factor: 9.079
Authors: W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder Journal: N Engl J Med Date: 1987-08-06 Impact factor: 91.245
Authors: Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison Journal: Clin Infect Dis Date: 2013-12-06 Impact factor: 9.079
Authors: Joseph N Jarvis; Andrew Boulle; Angela Loyse; Tihana Bicanic; Kevin Rebe; Anthony Williams; Thomas S Harrison; Graeme Meintjes Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Serisha D Naicker; Carolina Firacative; Erika van Schalkwyk; Tsidiso G Maphanga; Juan Monroy-Nieto; Jolene R Bowers; David M Engelthaler; Wieland Meyer; Nelesh P Govender Journal: PLoS Negl Trop Dis Date: 2022-06-29
Authors: Kaitlin Benedict; Jeremy A W Gold; Stephanie Dietz; Seher Anjum; Peter R Williamson; Brendan R Jackson Journal: Open Forum Infect Dis Date: 2022-05-16 Impact factor: 4.423
Authors: Michael J Davis; Rachel E Martin; Giovana M Pinheiro; Elizabeth S Hoke; Shannon Moyer; Katrin D Mayer-Barber; Yun C Chang; Kyung J Kwon-Chung Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786